

# NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes

Vladimir Zdravkovic<sup>1</sup>, Violeta Mladenovic<sup>2</sup>, Maja Colic<sup>3</sup>, Dragic Bankovic<sup>3</sup>, Zorica Lazic<sup>2</sup>, Marina Petrovic<sup>2</sup>, Ivan Simic<sup>1</sup>, Slavko Knezevic<sup>2</sup>, Sveto Pantovic<sup>4</sup>, Aleksandar Djukic<sup>2</sup>, Nemanja Zdravkovic<sup>3</sup>

<sup>1</sup>Department of Cardiology, Clinical Centre Kragujevac, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

<sup>2</sup>Clinic for Internal Medicine, Clinical Centre Kragujevac, Kragujevac, Serbia

<sup>3</sup>Centre for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

<sup>4</sup>Department of Gynaecology and Obstetrics, Clinical Centre of Serbia, Belgrade, Serbia

## Abstract

**Background and aim:** N terminal-proB-type natriuretic peptide (NT-proBNP) is synthesised and secreted from the ventricular myocardium. This marker is known to be elevated in patients with acute coronary syndromes (ACS). We evaluated NT-proBNP as a significant diagnostic marker and an important independent predictor of short-term mortality (one month) in patients with ACS.

**Methods:** NT-proBNP and cardiac troponin I (cTI) were assessed in 134 consecutive patients (median age 66 years, 73% male) hospitalised for ACS in a cardiological university department. The patients were classified into ST-elevation ACS (STE-ACS, n = 74) and non-ST-elevation ACS (NSTEMI-ACS, n = 60) groups based on the ECG findings on admission. Patients with Killip class  $\geq$  II were excluded.

**Results:** The serum level of NT-proBNP on admission was significantly higher ( $p < 0.0005$ ), while there was no difference in cTI serum level in the NSTEMI-ACS patients compared to STE-ACS patients. There was a significant positive correlation between NT-proBNP and cTI in the NSTEMI-ACS ( $r = 0.338$ ,  $p = 0.008$ ) and STE-ACS ( $r = 0.441$ ,  $p < 0.0005$ ) patients. There was a significant difference in NT-proBNP ( $p < 0.0005$ ) and cTI ( $p < 0.0005$ ) serum level between ACS patients who died within 30 days or who survived after one month. The increased NT-proBNP level is the strongest predictor of mortality in ACS patients, also NT-proBNP cut-point level of 1,490 pg/mL is a significant independent predictor of mortality.

**Conclusions:** We demonstrated the differences and the correlation in the secretion of NT-proBNP and cTI in patients with STE-ACS vs. NSTEMI-ACS. Our results provide evidence that NT-proBNP is a significant diagnostic marker and an important independent predictor of short-term mortality in patients with ACS.

**Key words:** acute coronary syndromes, NT-proBNP, troponin I, prognosis

Kardiol Pol 2013; 71, 5: 472–479

## INTRODUCTION

B-type natriuretic peptide (BNP), cardiac neurohormone, and its N-terminal fragment (NT-proBNP) are synthesised and secreted from the ventricular myocardium. It is well known that stimulus for their release is the increase in left ventricular wall stress [1, 2]. These markers are known to be elevated in patients with acute coronary syndromes (ACS). In this regard, ventricular dysfunction and/or myocardial ischaemia per se can cause an increase in cardiac NT-proBNP expression followed by augmented secretion [3–6]. Also, these markers are closely linked to the prognosis as a powerful predictor of both

short and long-term mortality [7–10]. It has been shown that BNP and NT-proBNP levels predict heart failure and death after myocardial infarction (MI) [11, 12].

Cardiac troponin (cT) is a regulatory protein which consists of three subunits I, T and C. Cardiac troponin I (cTI) is the biomarker of choice for the detection of myocardial necrosis as it is more specific and sensitive than classic cardiac enzymes (creatinine kinase, CK, CK-MB) [13]. Also, the determination of cTI is useful for estimating the extent of necrosis. For the patients with ACS, cTI is a prognostic indicator and allows the stratification of risk of cardiac events and mortality [14].

## Address for correspondence:

Nemanja Zdravkovic, MD, PhD, Assistant Professor, Centre for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica Street 69, 34000 Kragujevac, Serbia, tel: +38134306800113, fax: +38134306800112, e-mail: zdravkovic\_nemanja@yahoo.com

Received: 04.04.2012 Accepted: 12.12.2012

Copyright © Polskie Towarzystwo Kardiologiczne













